Cannovum AG enters cannabis market segment Dronabinol

Cannovum is pleased to announce a strategic supply partnership for Dronabinol with a European medical cannabis supplier. Products are expected to be sold starting from August as part of the Cannovum brand range.

 Cannovum AG enters cannabis market segment Dronabinol

 

Berlin, 15th June 2021. Cannovum AG (stock markets Düsseldorf, München, Hamburg, Berlin, gettex: ISIN DE000A2LQU21) is pleased to announce a strategic supply partnership for Dronabinol with a  European medical cannabis supplier. Products are expected to be sold starting  from August as part of the Cannovum brand range, with a signature supply contract initially running until the end of 2023.
  
Cannovum is expanding its medical cannabis portfolio by adding Dronabinol  through its licensed subsidiary, Cannovum Health eG. Dronabinol is a synthesized cannabinoid first prescribable in 1998 and now primarily used in pain therapy. By adding this established medication to the product portfolio, Cannovum takes another step to ensure best possible patient care: only a full  range of medical cannabis medication options grants doctors the opportunity  to find the optimum individual treatment for each patient. 
 
"The market for dronabinol has a volume of over €45 million in  Germany alone. The inclusion in our portfolio under our own brand is an  important milestone to provide patients in Germany and later Europe with a  comprehensive range of medicinal cannabis. Cannabis extracts are to follow  next," says Pia Marten, CEO of Cannovum AG.
 
In order to support doctors and pharmacists in finding the best possible treatment, Cannovum's pharmaceutical representatives have undergone intensive training on the full spectrum of Dronabinol with established medical  professionals. Experience and expertise are key components in providing the best possible patient care, because every patient deserves the best therapy.

 

About Cannovum:

Cannovum AG is the first German listed medical cannabis company. The shares are traded on the Düsseldorf, Munich, Berlin, Hamburg and gettex stock exchanges. Through its subsidiary Cannovum Health eG, Cannovum is a fully licensed pharmaceutical wholesaler, importer and manufacturer of high-quality medical cannabis products based in Berlin. The company focuses on the import of high-quality cannabinoid products, medical-scientific education and all-encompassing distribution for simplified and facilitated access to cannabis-based therapies.

Contact:

Linda Rasch, Head of Communications, Cannovum AG,

Phone +49 30 3982 163 62

linda.rasch@cannovum.com

 

 

Read more
Download pdf

Mehr News

Investment
April 2022

Cannovum AG resolves capital increase from authorized capital excluding subscription rights

The Management Board of Cannovum AG today resolved to increase the share capital.

Investment
February 2022

Cannovum AG launches Cannabis Medical Education Platform

Cannovum Medical Education (CME) is a free, comprehensive virtual continuing education platform for medical cannabis, in which the medical-therapeutic basics of medical cannabis are scientifically prepared.

Investment
January 2022

Cannovum AG now offers Next Day Delivery for medical cannabis

From now on, delivery to every pharmacy throughout Germany will take place directly on the next working day if the order is placed by 12:30 pm.